Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 8/20 | 0.64 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498213 | 0.85 | SLC5A1 (0.47) | SLC5A1SLC5A2TP53ALOX12SCN9A | |
| SCHEMBL28180133 | 0.78 | SLC5A1 (0.67) | SLC5A1SLC5A2APPTP53ALOX12 | |
| SCHEMBL497485 | 0.75 | SLC5A1 (0.44) | SLC5A1SLC5A2APPTP53SCN9A | |
| SCHEMBL497636 | 0.74 | NR1H4 (0.44) | SLC5A1SLC5A2TP53ALOX12MAPT | |
| SCHEMBL20077902 | 0.71 | SLC5A1 (0.51) | SLC5A1SLC5A2TP53MAPT | |
| SCHEMBL498090 | 0.71 | SLC5A1 (0.46) | SLC5A1SLC5A2TP53ALOX12SCN9A | |
| SCHEMBL20951988 | 0.70 | ALDH1A1 (0.65) | SLC5A1SLC5A2TP53SCN9AMAPT | |
| SCHEMBL20951787 | 0.70 | SLC5A1 (0.50) | SLC5A1SLC5A2TP53MAPT | |
| SCHEMBL30617260 | 0.70 | SLC5A1 (0.50) | SLC5A1SLC5A2TP53MAPT | |
| SCHEMBL30617269 | 0.70 | ALDH1A1 (0.65) | SLC5A1SLC5A2TP53SCN9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | SLC5A1 264/4885SLC5A2 321/4885APP 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.